Skip to main content
260 search results for:

Spondyloarthropathies 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 23-07-2021 | Adis Journal Club | Article
    Rheumatology and Therapy

    TNF-α Blockers Showed Prophylactic Effects in Preventing COVID-19 in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthropathies: A Case–Control Study

    TNF-α blockers are prescribed to treat various autoimmune disorders, including rheumatoid arthritis (RA) and seronegative spondyloarthropathies (SpA).

  2. 01-05-2018 | Channel

    Spondyloarthropathies

  3. 26-09-2017 | Inflammation | Image

    Seronegative spondyloarthropathies

    Seronegative spondyloarthropathies (SpA) are a group of chronic autoimmune inflammatory joint diseases predominantly affecting the axial skeleton and often accompanied by a peripheral arthritis.

  4. 26-09-2017 | Inflammation | Image

    Radiographic features of spondyloarthropathies

    As described on the previous slide, the pathological hallmarks of peripheral involvement of the spondyloarthropathies include synovitis, erosions, enthesitis, new bone formation, and dactylitis.

  5. play
    23-11-2022 | ACR 2022 | Conference coverage | Video

    SURPASS: Secukinumab vs adalimumab biosimilar in axSpA

    Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.

  6. 17-11-2022 | ACR 2022 | Conference coverage | Article

    Secukinumab comparable to adalimumab biosimilar in axSpA

    Researchers have found that secukinumab performs equally well to adalimumab biosimilar for the treatment of radiographic axial spondyloarthritis in a head-to-head trial.

  7. 09-11-2022 | Pregnancy | News | Article

    Pre-eclampsia warning for women with PsA or RA

    The risk for pre-eclampsia is increased in pregnant women with psoriatic arthritis or severe rheumatoid arthritis, but not those with axial spondyloarthritis, suggests research published in RMD Open .

  8. 13-10-2022 | Spondyloarthropathies | News | Article

    Study confirms benefits of physical activity in people with SpA

    Findings from a randomized controlled trial provide further evidence to support the beneficial impact of physical activity in people with spondyloarthritis.

  9. 08-09-2022 | Axial spondyloarthritis | News | Article

    Pregnancy outcome data ‘reassuring’ for women with axSpA

    Women with axial spondyloarthritis have “very low” rates of adverse pregnancy outcomes, show observational data from European pregnancy registries.

  10. 30-08-2022 | COVID-19 | News | Article

    Studies bolster evidence for COVID-19 vaccination in young people with RMDs

    Reassuring safety results in adolescents with a range of RMDs The second study, from Kimme Hyrich (Manchester University NHS Foundation Trust, UK) and team, focused on the safety profile of COVID-19 vaccination in 36 adolescents (median age 15 years) with RMDs – including JIA (42%), SLE (14%), and spondyloarthropathies (14%) – who were included in the EULAR COVAX registry in 2021–2022.

  11. 18-08-2022 | Spondyloarthropathies | News | Article

    Dermatology clinic screening offers easy opportunity for identifying axPsA

    Early identification of axial psoriatic arthritis might be aided by screening people with psoriasis for signs of axial involvement during routine dermatology check-ups, research suggests.

  12. 17-08-2022 | Spondyloarthropathies | News | Article

    Infliximab potential treatment option for juvenile-onset spondyloarthritis

    Infliximab appears efficacious for patients with juvenile-onset spondyloarthritis who have failed to respond to conventional treatment, phase 3 study findings show.

  13. 09-08-2022 | Axial spondyloarthritis | News | Article

    Substantial lifetime risk for axSpA among relatives of patients with ankylosing spondylitis

    A 35-year follow-up study has identified a 27.1% lifetime recurrence rate of axial spondyloarthritis among first-degree relatives of patients with human leukocyte antigen HLA-B27-positive ankylosing spondylitis.

  14. 05-08-2022 | Biologics | News | Article

    Support for long-term use of biologics in people with HIV

    TNF inhibitors have good long-term effectiveness and are well tolerated in HIV-positive individuals with rheumatic diseases, researchers report.

  15. 19-07-2022 | Bimekizumab | News | Article

    Bimekizumab demonstrates sustained benefits in PsA, ankylosing spondylitis

    Follow-up results from the BE ACTIVE and BE AGILE phase 2b trials show that the efficacy and safety profiles of bimekizumab are maintained for up to 3 years in patients with psoriatic arthritis or ankylosing spondylitis.

  16. 25-05-2022 | Bimekizumab | Feature | Article
    Updated June 2022

    A quick guide to the phase 3 trials of bimekizumab in spondyloarthritis

    Summary of the phase 3 trials investigating the IL-17A/IL-17F inhibitor bimekizumab in patients with ankylosing spondylitis, nonradiographic axial spondyloarthritis, or psoriatic arthritis.

  17. play
    20-06-2022 | EULAR 2022 | Conference coverage | Video

    BE MOBILE 1 and 2: How might bimekizumab impact axSpA clinical practice?

    Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials.

  18. 21-06-2022 | Glucocorticoids | News | Article

    Low-dose glucocorticoids show no negative impact on BMD

    Low glucocorticoid doses are not associated with reduced bone mineral density in people with inflammatory rheumatic and musculoskeletal diseases, observational study findings indicate.

  19. 01-06-2022 | EULAR 2022 | Conference coverage | Article

    BE MOBILE trials support bimekizumab for the treatment of axSpA

    The results of two phase 3 studies suggest that dual inhibition of IL-17A and IL-17F with bimekizumab may represent a promising treatment option for nonradiographic axial spondyloarthritis and ankylosing spondylitis.

  20. 01-06-2022 | EULAR 2022 | Conference coverage | Article

    SELECT-AXIS 2: Upadacitinib shows promise for axSpA

    Findings from the SELECT-AXIS 2 trial provide further support for the benefits of upadacitinib across the spectrum of axial spondyloarthritis.

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.